

# Vito Amoroso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/170975/publications.pdf>

Version: 2024-02-01

61  
papers

1,092  
citations

471371

17  
h-index

434063

31  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2167-e2176.	1.8	3
2	Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of WHO fracture risk assessment tool (FRAX) and bone mineral density in real-life clinical practice. <i>Journal of Bone Oncology</i> , 2022, 33, 100421.	1.0	10
3	Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study. <i>Supportive Care in Cancer</i> , 2022, , .	1.0	1
4	Efficacy of the DigniCap System in preventing chemotherapy-induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device. <i>International Journal of Nursing Practice</i> , 2021, 27, e12888.	0.8	5
5	The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy. <i>JBMR Plus</i> , 2021, 5, e10440.	1.3	16
6	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
7	Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy. <i>Scientific Reports</i> , 2021, 11, 12975.	1.6	10
8	Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis. <i>Endocrine-Related Cancer</i> , 2021, 28, 593-604.	1.6	8
9	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINTenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	1.3	8
10	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 707346.	1.3	1
11	The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili di Brescia: Efficacy of Preventive Measures. <i>Frontiers in Oncology</i> , 2020, 10, 1574.	1.3	5
12	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 13589.	1.6	27
13	Should everolimus be stopped after radiological progression in metastatic insulinoma? A consensus point of view. <i>Endocrine</i> , 2020, 69, 481-484.	1.1	5
14	Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies. <i>Journal of Clinical Oncology</i> , 2020, 38, 3363-3366.	0.8	22
15	Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. <i>Journal of Geriatric Oncology</i> , 2020, 11, 976-981.	0.5	5
16	Excess of second tumors in denosumab-treated patients: a metabolic hypothesis. <i>Future Oncology</i> , 2019, 15, 2319-2321.	1.1	11
17	Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy. <i>JAMA Network Open</i> , 2019, 2, e1911080.	2.8	26
18	Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed. <i>Journal of Clinical Oncology</i> , 2019, 37, 350-351.	0.8	25

#	ARTICLE	IF	CITATIONS
19	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, 137-145.e4.	1.1	9
20	Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. <i>Journal of Surgical Research</i> , 2019, 236, 288-299.	0.8	7
21	Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. <i>Lung Cancer</i> , 2019, 127, 12-18.	0.9	40
22	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 458-467.	0.3	22
23	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 165-175.e2.	0.9	41
24	Prevalence, Severity, and Self-Reported Characteristics of Taste Alterations in Patients Receiving Chemotherapy. <i>Oncology Nursing Forum</i> , 2018, 45, 342-353.	0.5	26
25	IFN- $\gamma$ in advanced well-differentiated neuroendocrine tumors: the neglected drug?. <i>Future Oncology</i> , 2018, 14, 897-899.	1.1	1
26	Efficacy of topic steroids in the management of asthma and chronic obstructive pulmonary disease in advanced non-small cell lung cancer patients during treatment with nivolumab. <i>Minerva Respiratory Medicine</i> , 2018, 57, .	0.1	0
27	Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 39-46.	3.4	14
28	Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study. <i>Oncology</i> , 2018, 94, 10-15.	0.9	19
29	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , 2017, 97, 147-152.	1.4	33
30	When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1487-1488.	0.8	3
31	Regression of advanced neuroendocrine tumors among patients receiving placebo. <i>Endocrine-Related Cancer</i> , 2017, 24, L13-L16.	1.6	5
32	Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2017, 59, 117-122.	3.4	61
33	The involvement of early stage breast cancer patients during oncology consultations in Italy: a multi-centred, randomized controlled trial of a question prompt sheet versus question listing. <i>BMJ Open</i> , 2017, 7, e015079.	0.8	14
34	Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues. <i>Journal of Clinical Oncology</i> , 2016, 34, 3709-3710.	0.8	3
35	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221.	2.0	33
36	Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?. <i>Future Oncology</i> , 2015, 11, 2853-2856.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower-Risk Patients With Early-Stage Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 290-290.	0.8	2
38	Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1357-1359.	13.9	22
39	Testosterone serum levels and prostate cancer prognosis: the double face of Janus. <i>Future Oncology</i> , 2014, 10, 1113-1115.	1.1	6
40	Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. <i>Journal of Clinical Oncology</i> , 2014, 32, 3883-3891.	0.8	194
41	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. <i>BMC Cancer</i> , 2014, 14, 184.	1.1	76
42	Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2014, 20, S26-S27.	0.7	0
43	Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1619-1635.	1.9	33
44	739 poster ACUTE TOXICITY IN PATIENTS TREATED POSTOPERATIVELY WITH CONCURRENT RADIOTHERAPY AND TAXANES FOR BREAST CANCER. A RETROSPECTIVE ANALYSIS. <i>Radiotherapy and Oncology</i> , 2011, 99, S293.	0.3	0
45	Circulating Tumor Cells as Predictors of Prognosis in Metastatic Breast Cancer: Clinical Application outside a Clinical Trial. <i>Tumori</i> , 2011, 97, 737-742.	0.6	11
46	P4-07-19: Bone Marrow Involvement Is Associated with High Numbers of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients.. , 2011, , .		0
47	III-IV line of target therapy in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2010, 28, e15148-e15148.	0.8	1
48	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. <i>Annals of Oncology</i> , 2009, 20, 1062-1067.	0.6	18
49	Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. <i>Journal of Neuro-Oncology</i> , 2009, 91, 47-50.	1.4	35
50	Is Irinotecan Plus Docetaxel Useful as Second-Line Therapy in Advanced Non-small Cell Lung Cancer?. <i>Journal of Thoracic Oncology</i> , 2008, 3, 405-411.	0.5	1
51	Bi-weekly fixed dose of gemcitabine (GEM) plus 24 hours infusion of cisplatin (CDDP) in advanced/metastatic pancreatic cancer (APC) patients: A phase II study. <i>Journal of Clinical Oncology</i> , 2008, 26, 15639-15639.	0.8	1
52	Neurotoxicity in older colorectal patients with diabetes treated with oxaliplatin schedule: Our experience. <i>Journal of Clinical Oncology</i> , 2008, 26, 20724-20724.	0.8	0
53	Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria. <i>BMC Cancer</i> , 2007, 7, 94.	1.1	17
54	Loss of CXCR4 nuclear immunoreactivity in synovial sarcoma (SS) correlates with poor survival. <i>Journal of Clinical Oncology</i> , 2007, 25, 10069-10069.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 185-190.	1.1	82
56	upper gastrointestinal tumors. <i>Annals of Oncology</i> , 2006, 17, ix308-ix326.	0.6	5
57	Intra-arterial Chemotherapy in Elderly Patients with Invasive Bladder Cancer. <i>Clinical Oncology</i> , 2005, 17, 663-664.	0.6	1
58	An Alternating Regimen of Irinotecan/ 5-Fluorouracil/Folinic Acid and Oxaliplatin/ 5-Fluorouracil/Folinic Acid in Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncology</i> , 2005, 69, 283-289.	0.9	4
59	A Retrospective Series of Long-Term Survivors of Metastatic Breast Cancer in Complete Remission. <i>Oncology</i> , 2005, 68, 48-51.	0.9	7
60	Epirubicin, Cisplatin, and Raltitrexed in Patients With Advanced Gastric and Hepatobiliary Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 445-448.	0.6	8
61	BCL-2 Immunohistochemical Evaluation in B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Before Treatment with Fludarabine and 2-Chloro-Deoxy-Adenosine. <i>Leukemia and Lymphoma</i> , 1998, 28, 567-572.	0.6	35